首页> 美国卫生研究院文献>other >Using bioluminescent resonance energy transfer (BRET) to characterize agonist-induced arrestin recruitment to modified and unmodified G protein-coupled receptors (GPCRs)
【2h】

Using bioluminescent resonance energy transfer (BRET) to characterize agonist-induced arrestin recruitment to modified and unmodified G protein-coupled receptors (GPCRs)

机译:使用生物发光共振能量转移(BRET)表征激动剂诱导的抑制蛋白募集到修饰和未修饰的G蛋白偶联受体(GPCR)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

G protein-coupled receptors (GPCRs) represent ~25% of current drug targets. Ligand binding to these receptors activates G proteins and arrestins, which are involved in differential signaling pathways. Functionally selective or biased ligands activate one of these two pathways and may be superior medications for certain diseases states. The identification of these ligands requires robust drug screening assays for both G protein and arrestin activity. Here we describe in detail the technical aspects of two bioluminescence resonance energy (BRET)-based assays that can be used to monitor arrestin recruitment to GPCRs. One assay requires modification of GPCRs by fusion to a BRET donor or acceptor moiety, whereas the other can detect recruitment of arrestin to unmodified GPCRs.
机译:G蛋白偶联受体(GPCR)占当前药物靶标的 25%。与这些受体结合的配体激活了G蛋白和抑制蛋白,它们参与了不同的信号通路。功能选择性或偏向配体激活这两种途径之一,可能是某些疾病状态的上乘药物。这些配体的鉴定要求针对G蛋白和抑制蛋白的活性进行可靠的药物筛选测定。在这里,我们详细描述了两种基于生物发光共振能量(BRET)的检测的技术方面,这些检测可用于监测抑制蛋白募集到GPCR中。一种测定需要通过与BRET供体或受体部分融合来修饰GPCR,而另一种则可以检测到抑制素募集到未修饰的GPCR中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号